{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T01:47:14Z","timestamp":1780710434452,"version":"3.54.1"},"reference-count":42,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Three variants of the major rubella virus (RV) E1 protein virus-neutralizing epitope from position 214 to 285 were exposed on the hepatitis B virus (HBV) C-terminally truncated core (HBc\u0394) in a virus-like particle (VLP) vector and were produced in\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            . All three chimeras demonstrated VLPs in bacterial cell lysates, but only HBc\u0394-E1(245-285) demonstrated the correct VLP structure after purification. The other chimeras, HBc\u0394-E1(214-285) and HBc\u0394-E1(214-240), appeared after purification as non-VLP aggregates of 100 to 900 nm in diameter according to dynamic light scattering data. All three variants possessed the intrinsic antigenic activity of RV E1, since they were recognized by natural human anti-RV E1 antibodies and induced an anti-RV E1 response in mice. HBc\u0394-E1(214-240) and HBc\u0394-E1(245-285) can be regarded as prototypes for a putative RV vaccine because they were able to induce antibodies recognizing natural RV E1 protein in RV diagnostic kits.\n          <\/jats:p>","DOI":"10.1128\/cvi.00533-13","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T01:54:16Z","timestamp":1378346056000},"page":"1719-1728","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":14,"title":["Chimeric Derivatives of Hepatitis B Virus Core Particles Carrying Major Epitopes of the Rubella Virus E1 Glycoprotein"],"prefix":"10.1128","volume":"20","author":[{"given":"Dace","family":"Skrastina","sequence":"first","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivars","family":"Petrovskis","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasa","family":"Petraityte","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Sominskaya","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velta","family":"Ose","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilva","family":"Liekni\u0146a","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Bogans","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kestutis","family":"Sasnauskas","sequence":"additional","affiliation":[{"name":"Institute of Biotechnology, Vilnius, Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Pumpens","sequence":"additional","affiliation":[{"name":"Latvian Biomedical Research and Study Centre, Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/clinids\/7.Supplement_1.S95","article-title":"Fetal risk associated with rubella vaccine: an update","volume":"7","author":"Bart SW","year":"1985","unstructured":"BartSWStelterHCPrebludSRWilliamsNMOrensteinWABartKJHinmanARHerrmannKL. 1985. Fetal risk associated with rubella vaccine: an update. Rev. Infect. Dis. 7(Suppl 1):S95\u2013S102.","journal-title":"Rev. Infect. Dis."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archpedi.1965.02090030401007","article-title":"Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus","volume":"110","author":"Plotkin SA","year":"1965","unstructured":"PlotkinSACornfeldDIngallsTH. 1965. Studies of immunization with living rubella virus. Trials in children with a strain cultured from an aborted fetus. Am. J. Dis. Child. 110:381\u2013389.","journal-title":"Am. J. Dis. Child."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/oxfordjournals.aje.a120757","article-title":"A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion","volume":"86","author":"Plotkin SA","year":"1967","unstructured":"PlotkinSAFarquharJKatzMIngallsTH. 1967. A new attenuated rubella virus grown in human fibroblasts: evidence for reduced nasopharyngeal excretion. Am. J. Epidemiol. 86:468\u2013477.","journal-title":"Am. J. Epidemiol."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0891-5520(20)30323-8","article-title":"Measles, mumps, and rubella vaccines","volume":"4","author":"Wharton M","year":"1990","unstructured":"WhartonMCochiSLWilliamsWW. 1990. Measles, mumps, and rubella vaccines. Infect. Dis. Clin. North. Am. 4:47\u201373.","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.46.3.964-973.1983"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.57.3.893-898.1986"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.2.961-968.1993"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/vim.2000.13.83","article-title":"Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells","volume":"13","author":"Cordoba P","year":"2000","unstructured":"CordobaPGrutadauriaSCuffiniCZapataM. 2000. Neutralizing monoclonal antibody to the E1 glycoprotein epitope of rubella virus mediates virus arrest in VERO cells. Viral Immunol. 13:83\u201392.","journal-title":"Viral Immunol."},{"key":"e_1_3_2_10_2","first-page":"33","article-title":"Characterization of rubella virus-specific antibody responses by using synthetic peptides","volume":"29","author":"Mitchell LA","year":"1993","unstructured":"MitchellLADecarieDTingleAJZreinMLacroixM. 1993. Characterization of rubella virus-specific antibody responses by using synthetic peptides. Virus Res. 29:33\u201357.","journal-title":"Virus Res."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0042-6822(92)90572-7","article-title":"Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus","volume":"189","author":"Chaye H","year":"1992","unstructured":"ChayeHChongPTripetBBrushBGillamS. 1992. Localization of the virus neutralizing and hemagglutinin epitopes of E1 glycoprotein of rubella virus. Virology 189:483\u2013492.","journal-title":"Virology"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF01322168","article-title":"Localization of the rubella E1 epitopes","volume":"98","author":"Terry GM","year":"1988","unstructured":"TerryGMHo-TerryLLondesboroughPReesKR. 1988. Localization of the rubella E1 epitopes. Arch. Virol. 98:189\u2013197.","journal-title":"Arch. Virol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.vaccine.2004.06.030","article-title":"A recombinant rubella E1 glycoprotein as a rubella vaccine candidate","volume":"23","author":"Perrenoud G","year":"2004","unstructured":"PerrenoudGMesserliFThierryACBeltraminelliNCousinPFaselNValletVDemotzSDuchosalMAMoulonC. 2004. A recombinant rubella E1 glycoprotein as a rubella vaccine candidate. Vaccine 23:480\u2013488.","journal-title":"Vaccine"},{"key":"e_1_3_2_14_2","first-page":"12","volume-title":"Modern approaches to new vaccines: prevention of AIDS and other viral, bacterial and parasitic diseases","author":"Newton SE","year":"1987","unstructured":"NewtonSEClarkeBEAppleyardGFrancisMJCarrollARRowlandsDJSkehelJBrownF. 1987. New approaches to FMDV antigen presentation using vaccinia virus, p 12\u201321. In ChanockRMLernerRABrownFGinsbergH (ed), Vaccines 87. Modern approaches to new vaccines: prevention of AIDS and other viral, bacterial and parasitic diseases. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/330381a0","article-title":"Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein","volume":"330","author":"Clarke BE","year":"1987","unstructured":"ClarkeBENewtonSECarrollARFrancisMJAppleyardGSyredADHighfieldPERowlandsDJBrownF. 1987. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 330:381\u2013384.","journal-title":"Nature"},{"key":"e_1_3_2_16_2","first-page":"169","article-title":"Recombinant capsid structures for exposure of protein antigenic epitopes","volume":"6","author":"Borisova G","year":"1987","unstructured":"BorisovaGBunduleMGrinsteinEDreilinaDDreimaneAKalisJKozlovskayaTLosevaVOseVPumpenPPushkoPSnikereDStankevicaETsibinoginVGrenEJ. 1987. Recombinant capsid structures for exposure of protein antigenic epitopes. Mol. Gen. (Life Sci. Adv.) 6:169\u2013174.","journal-title":"Mol. Gen. (Life Sci. Adv.)"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000050037","article-title":"HBV core particles as a carrier for B cell\/T cell epitopes","volume":"44","author":"Pumpens P","year":"2001","unstructured":"PumpensPGrensE. 2001. HBV core particles as a carrier for B cell\/T cell epitopes. Intervirology 44:98\u2013114.","journal-title":"Intervirology"},{"key":"e_1_3_2_18_2","first-page":"249","volume-title":"Artificial DNA: methods and applications","author":"Pumpens P","year":"2002","unstructured":"PumpensPGrensE. 2002. Artificial genes for chimeric virus-like particles, p 249\u2013327. In KhudyakovYEFieldsHA (ed), Artificial DNA: methods and applications. CRC Press LLC, Boca Raton, FL."},{"key":"e_1_3_2_19_2","first-page":"205","volume-title":"Medicinal protein engineering","author":"Pumpens P","year":"2008","unstructured":"PumpensPUlrichRSasnauskasKKazaksAOseVGrensE. 2008. Construction of novel vaccines on the basis of the virus-like particles: hepatitis B virus proteins as vaccine carriers, p 205\u2013248. In KhudyakovY (ed), Medicinal protein engineering. CRC Press, Taylor & Francis Group, Boca Raton, FL."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1586\/erv.12.150","article-title":"Hepatitis B core-based virus-like particles to present heterologous epitopes","volume":"12","author":"Roose K","year":"2013","unstructured":"RooseKDe BaetsSSchepensBSaelensX. 2013. Hepatitis B core-based virus-like particles to present heterologous epitopes. Expert Rev. Vaccines 12:183\u2013198.","journal-title":"Expert Rev. Vaccines"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1073\/pnas.89.21.10046","article-title":"Hepatitis B virus capsid particles are assembled from core-protein dimer precursors","volume":"89","author":"Zhou S","year":"1992","unstructured":"ZhouSStandringDN. 1992. Hepatitis B virus capsid particles are assembled from core-protein dimer precursors. Proc. Natl. Acad. Sci. U. S. A. 89:10046\u201310050.","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1021\/bi00015a003","article-title":"Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly","volume":"34","author":"Wingfield PT","year":"1995","unstructured":"WingfieldPTStahlSJWilliamsRWStevenAC. 1995. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry 34:4919\u20134932.","journal-title":"Biochemistry"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02033-09"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0092-8674(94)90142-2","article-title":"Three dimensional structure of hepatitis B virus core particles determined by electron cryo-microscopy","volume":"77","author":"Crowther RA","year":"1994","unstructured":"CrowtherRAKiselevNAB\u00f6ttcherBBerrimanJABorisovaGPOseVPumpensP. 1994. Three dimensional structure of hepatitis B virus core particles determined by electron cryo-microscopy. Cell 77:943\u2013950.","journal-title":"Cell"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jmb.2012.06.032","article-title":"Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies","volume":"423","author":"Roseman AM","year":"2012","unstructured":"RosemanAMBorschukovaOBerrimanJAWynneSAPumpensPCrowtherRA. 2012. Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies. J. Mol. Biol. 423:63\u201378.","journal-title":"J. Mol. Biol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1097-2765(01)80009-5","article-title":"The crystal structure of the human hepatitis B virus capsid","volume":"3","author":"Wynne SA","year":"1999","unstructured":"WynneSACrowtherRALeslieAG. 1999. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3:771\u2013780.","journal-title":"Mol. Cell"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/j.vaccine.2006.02.051","article-title":"Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV)","volume":"24","author":"Mihailova M","year":"2006","unstructured":"MihailovaMBoosMPetrovskisIOseVSkrastinaDFiedlerMSominskayaIRossSPumpensPRoggendorfMViazovS. 2006. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine 24:4369\u20134377.","journal-title":"Vaccine"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0161-5890(93)90051-C","article-title":"Epitopes recognized by antibodies to denatured core protein of hepatitis B virus","volume":"30","author":"Bichko V","year":"1993","unstructured":"BichkoVSchodelFNassalMGrenEBerzinshIBorisovaGMiskaSPetersonDLGrenEPushkoPWillH. 1993. Epitopes recognized by antibodies to denatured core protein of hepatitis B virus. Mol. Immunol. 30:221\u2013231.","journal-title":"Mol. Immunol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1515\/BC.1999.050","article-title":"Yeast cells allow high-level expression and formation of polyomavirus-like particles","volume":"380","author":"Sasnauskas K","year":"1999","unstructured":"SasnauskasKBuzaiteOVogelFJandrigBRazanskasRStaniulisJScherneckSKr\u00fcgerDHUlrichR. 1999. Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol. Chem. 380:381\u2013386.","journal-title":"Biol. Chem."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jbiotec.2004.04.010","article-title":"High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae","volume":"111","author":"Razanskiene A","year":"2004","unstructured":"RazanskieneASchmidtJGeldmacherARitziANiedrigMLundkvistAKr\u00fcgerDHMeiselHSasnauskasKUlrichR. 2004. High yields of stable and highly pure nucleocapsid proteins of different hantaviruses can be generated in the yeast Saccharomyces cerevisiae. J. Biotechnol. 111:319\u2013333.","journal-title":"J. Biotechnol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000067922","article-title":"Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae","volume":"45","author":"Sasnauskas K","year":"2002","unstructured":"SasnauskasKBulavaiteAHaleAJinLKnowlesWAGedvilaiteADargevici\u016bteABartkevici\u016bteDZvirblieneAStaniulisJBrownDWUlrichR. 2002. Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 45:308\u2013317.","journal-title":"Intervirology"},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jbiotec.2003.10.018","article-title":"Synthesis of the measles virus nucleoprotein in yeast Pichia pastoris and Saccharomyces cerevisiae","volume":"107","author":"Slibinskas R","year":"2004","unstructured":"SlibinskasRSamuelDGedvilaiteAStaniulisJSasnauskasK. 2004. Synthesis of the measles virus nucleoprotein in yeast Pichia pastoris and Saccharomyces cerevisiae. J. Biotechnol. 107:115\u2013124.","journal-title":"J. Biotechnol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/viro.1997.8462","article-title":"Analyses of disulfides present in the rubella virus E1 glycoprotein","volume":"230","author":"Gros C","year":"1997","unstructured":"GrosCLinderMWenglerGWenglerG. 1997. Analyses of disulfides present in the rubella virus E1 glycoprotein. Virology 230:179\u2013186.","journal-title":"Virology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0065-3527(08)60328-0","article-title":"Molecular biology of rubella virus","volume":"44","author":"Frey TK","year":"1994","unstructured":"FreyTK. 1994. Molecular biology of rubella virus. Adv. Virus Res. 44:69\u2013160.","journal-title":"Adv. Virus Res."},{"key":"e_1_3_2_35_2","first-page":"29","article-title":"Effects of disulfide bridges glycoprotein E1 on fusogenic activity of Rubella virus","volume":"53","author":"Liu XL","year":"2009","unstructured":"LiuXLWuBZhangWQSongYYXuHZWangGTWangZY. 2009. Effects of disulfide bridges glycoprotein E1 on fusogenic activity of Rubella virus. Acta Virol. 53:29\u201334.","journal-title":"Acta Virol."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1743-422X-7-146","article-title":"A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice","volume":"7","author":"Spohn G","year":"2010","unstructured":"SpohnGJenningsGTMartinaBEKellerIBeckMPumpensPOsterhausADBachmannMF. 2010. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J. 7:146.","journal-title":"Virol. J."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd1284","article-title":"Therapeutic vaccination for chronic diseases: a new class of drugs in sight","volume":"3","author":"Bachmann MF","year":"2004","unstructured":"BachmannMFDyerMR. 2004. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat. Rev. Drug Discov. 3:81\u201388.","journal-title":"Nat. Rev. Drug Discov."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s12033-012-9598-4","article-title":"Construction and characterization of virus-like particles: a review","volume":"53","author":"Zeltins A","year":"2013","unstructured":"ZeltinsA. 2013. Construction and characterization of virus-like particles: a review. Mol. Biotechnol. 53:92\u2013107.","journal-title":"Mol. Biotechnol."},{"key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000346773","article-title":"Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures","volume":"56","author":"Pushko P","year":"2013","unstructured":"PushkoPPumpensPGrensE. 2013. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 56:141\u2013165.","journal-title":"Intervirology"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg AS","year":"2006","unstructured":"RosenbergAS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8:E501\u2013E507.","journal-title":"AAPS J."},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/S0264-410X(00)00032-3","article-title":"Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice","volume":"18","author":"Kelly EP","year":"2000","unstructured":"KellyEPGreeneJJKingADInnisBL. 2000. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18:2549\u20132559.","journal-title":"Vaccine"},{"key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines\u2014current status, problems and future prospects","volume":"13","author":"Gupta RK","year":"1995","unstructured":"GuptaRKSiberGR. 1995. Adjuvants for human vaccines\u2014current status, problems and future prospects. Vaccine 13:1263\u20131276.","journal-title":"Vaccine"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0014-5793(85)80771-7","article-title":"Subtype ayw variant of hepatitis B virus. DNA primary structure analysis","volume":"185","author":"Bichko V","year":"1985","unstructured":"BichkoVPushkoPDreilinaDPumpenPGrenE. 1985. Subtype ayw variant of hepatitis B virus. DNA primary structure analysis. FEBS Lett. 185:208\u2013212.","journal-title":"FEBS Lett."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00533-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00533-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:08Z","timestamp":1627591688000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00533-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1128\/CVI.00533-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00533-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"2013-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}